TapewireFind a company

organization · Reporting owner

5AM Partners VI, LLC

Disclosed activity across 7 companies

Tapewire entity
24241
SEC CIK
0001829051

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
5:01 Acquisition Corp.FVAM · Entity 14498910% ownerNovember 30, 2020December 01, 2020
Artiva Biotherapeutics, Inc.ARTV · Entity 540410% ownerJuly 22, 2024July 24, 2024
Latigo Biotherapeutics, Inc.LTGO · Entity 470910% ownerAugust 10, 2026August 12, 2026
Vor Biopharma Inc.VOR · Entity 476310% ownerNovember 16, 2021November 19, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

5:01 Acquisition Corp.

Report date November 30, 2020 · Filed December 01, 2020

Jointly reported with 5:01 Acquisition LLC, 5AM Ventures VI, L.P.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class B Common StockSEC Table II · derivative / convertible securityDirect1,944,068 Reported balance After 2020-11-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2020-11-30 · Other · Disposed 235,932 · Balance 1,944,068

F1: The shares of Class B common stock are convertible into shares of the issuer's Class A common stock on a one-for-one basis, subject to adjustment pursuant to certain anti-dilution rights, and have no expiration date.

F2: Represents the forfeiture of 235,932 previously reported shares that were subject to forfeiture in the event the underwriters of the initial public offering of the issuer's securities did not exercise in full their over-allotment option as described in the issuer's registration statement.

F3: 5AM Partners VI, LLC is the general partner of 5AM Ventures VI, L.P., the sole member of the Reporting Person, and may be deemed to have sole investment and voting power over the shares held by the Reporting Person.

Filing footnotes · ownership attribution and instrument terms

F1: The shares of Class B common stock are convertible into shares of the issuer's Class A common stock on a one-for-one basis, subject to adjustment pursuant to certain anti-dilution rights, and have no expiration date.

F2: Represents the forfeiture of 235,932 previously reported shares that were subject to forfeiture in the event the underwriters of the initial public offering of the issuer's securities did not exercise in full their over-allotment option as described in the issuer's registration statement.

F3: 5AM Partners VI, LLC is the general partner of 5AM Ventures VI, L.P., the sole member of the Reporting Person, and may be deemed to have sole investment and voting power over the shares held by the Reporting Person.

Artiva Biotherapeutics, Inc.

Report date July 22, 2024 · Filed July 24, 2024

Jointly reported with 5AM Ventures VI, L.P., 5AM Opportunities II (GP), LLC, 5AM Opportunities II, L.P., PARMAR KUSH, Schwab Andrew J.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy 5AM Ventures VI, L.P.1,171,250 Last balance in matching sequence After 2024-07-22 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 1 · 2024-07-22 · Conversion · Acquired 1,058,284 · Balance 1,058,284

F1: Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F2: The shares are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein.

Row 2 · 2024-07-22 · Other · Acquired 112,966 · Balance 1,171,250

F3: Represents the conversion of outstanding simple agreement for future equity in the amount of $1,152,253.93 into shares of the Issuer's common stock upon closing of the Issuer's IPO at a 15% discount to the IPO price.

F2: The shares are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy 5AM Opportunities II, L.P.1,182,054 Last balance in matching sequence After 2024-07-22 transaction · row 4 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 3 · 2024-07-22 · Other · Acquired 348,721 · Balance 348,721

F4: Represents the conversion of outstanding simple agreement for future equity in the amount of $3,556,957.78 into shares of the Issuer's common stock upon closing of the Issuer's IPO at a 15% discount to the IPO price.

F5: Shares are held by 5AM Opportunities II, L.P. ("Opportunities II"). 5AM Opportunities II (GP), LLC ("Opportunities II GP") is the general partner of Opportunities II and may be deemed to have sole investment and voting power over the shares held by Opportunities II. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Opportunities II GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities II. Each of Opportunities II GP, Dr. Parmar and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein.

Row 4 · 2024-07-22 · Purchase · Acquired 833,333 · Balance 1,182,054

F5: Shares are held by 5AM Opportunities II, L.P. ("Opportunities II"). 5AM Opportunities II (GP), LLC ("Opportunities II GP") is the general partner of Opportunities II and may be deemed to have sole investment and voting power over the shares held by Opportunities II. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Opportunities II GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities II. Each of Opportunities II GP, Dr. Parmar and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein.

Series A Preferred StockSEC Table II · derivative / convertible securityIndirectBy 5AM Ventures VI, L.P.0 Reported balance After 2024-07-22 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2024-07-22 · Conversion · Disposed 843,592 · Balance 0

F1: Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F2: The shares are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein.

Series B Preferred StockSEC Table II · derivative / convertible securityIndirectBy 5AM Ventures VI, L.P.0 Reported balance After 2024-07-22 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2024-07-22 · Conversion · Disposed 214,692 · Balance 0

F1: Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F2: The shares are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F2: The shares are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein.

F3: Represents the conversion of outstanding simple agreement for future equity in the amount of $1,152,253.93 into shares of the Issuer's common stock upon closing of the Issuer's IPO at a 15% discount to the IPO price.

F4: Represents the conversion of outstanding simple agreement for future equity in the amount of $3,556,957.78 into shares of the Issuer's common stock upon closing of the Issuer's IPO at a 15% discount to the IPO price.

F5: Shares are held by 5AM Opportunities II, L.P. ("Opportunities II"). 5AM Opportunities II (GP), LLC ("Opportunities II GP") is the general partner of Opportunities II and may be deemed to have sole investment and voting power over the shares held by Opportunities II. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Opportunities II GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities II. Each of Opportunities II GP, Dr. Parmar and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein.

Latigo Biotherapeutics, Inc.

Report date August 10, 2026 · Filed August 12, 2026

Jointly reported with 5AM Ventures VI, L.P., 5AM Opportunities II, L.P., 5AM Opportunities II (GP), LLC, PARMAR KUSH, Schwab Andrew J.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy 5AM Ventures VI, L.P.4,975,543 Reported balance After 2026-08-10 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2026-08-10 · Conversion · Acquired 4,975,543 · Balance 4,975,543

F1: Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date.

F2: The securities are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy 5AM Opportunities II, L.P.2,350,419 Reported balance After 2026-08-10 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2026-08-10 · Conversion · Acquired 2,350,419 · Balance 2,350,419

F1: Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date.

F3: The securities are directly held by 5AM Opportunities II, L.P. ("Opportunities II"). 5AM Opportunities II (GP), LLC ("Opportunities II GP") is the general partner of Opportunities II and may be deemed to have sole investment and voting power over the securities held by Opportunities II. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Opportunities II GP and may be deemed to have shared voting and investment power over the securities beneficially owned by Opportunities II. Each of Opportunities II GP, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein.

Series A Preferred StockSEC Table II · derivative / convertible securityIndirectBy 5AM Ventures VI, L.P.0 Reported balance After 2026-08-10 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-08-10 · Conversion · Disposed 3,152,305 · Balance 0

F1: Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date.

F2: The securities are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein.

Series A-2 Preferred StockSEC Table II · derivative / convertible securityIndirectBy 5AM Ventures VI, L.P.0 Reported balance After 2026-08-10 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2026-08-10 · Conversion · Disposed 1,823,238 · Balance 0

F1: Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date.

F2: The securities are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein.

Series A-2 Preferred StockSEC Table II · derivative / convertible securityIndirectBy 5AM Opportunities II, L.P.0 Reported balance After 2026-08-10 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2026-08-10 · Conversion · Disposed 866,018 · Balance 0

F1: Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date.

F3: The securities are directly held by 5AM Opportunities II, L.P. ("Opportunities II"). 5AM Opportunities II (GP), LLC ("Opportunities II GP") is the general partner of Opportunities II and may be deemed to have sole investment and voting power over the securities held by Opportunities II. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Opportunities II GP and may be deemed to have shared voting and investment power over the securities beneficially owned by Opportunities II. Each of Opportunities II GP, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein.

Series B Preferred StockSEC Table II · derivative / convertible securityIndirectBy 5AM Opportunities II, L.P.0 Reported balance After 2026-08-10 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2026-08-10 · Conversion · Disposed 1,484,401 · Balance 0

F1: Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date.

F3: The securities are directly held by 5AM Opportunities II, L.P. ("Opportunities II"). 5AM Opportunities II (GP), LLC ("Opportunities II GP") is the general partner of Opportunities II and may be deemed to have sole investment and voting power over the securities held by Opportunities II. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Opportunities II GP and may be deemed to have shared voting and investment power over the securities beneficially owned by Opportunities II. Each of Opportunities II GP, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date.

F2: The securities are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein.

F3: The securities are directly held by 5AM Opportunities II, L.P. ("Opportunities II"). 5AM Opportunities II (GP), LLC ("Opportunities II GP") is the general partner of Opportunities II and may be deemed to have sole investment and voting power over the securities held by Opportunities II. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Opportunities II GP and may be deemed to have shared voting and investment power over the securities beneficially owned by Opportunities II. Each of Opportunities II GP, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein.

Vor Biopharma Inc.

Report date November 16, 2021 · Filed November 19, 2021

Jointly reported with 5AM Ventures VI, L.P., 5AM Opportunities I, L.P., 5AM Opportunities I (GP), LLC, Schwab Andrew J.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee footnote4,595,089 Reported balance After 2021-11-16 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2021-11-16 · Sale · Disposed 238,870 · Balance 4,595,089

F1: The shares are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held directly by Ventures VI, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the issuer and files separate Section 16 reports.

Common StockSEC Table I · non-derivativeIndirectSee footnote1,766,634 Reported balance After 2021-11-16 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2021-11-16 · Sale · Disposed 91,836 · Balance 1,766,634

F2: The shares are directly held by 5AM Opportunities I, L.P ("Opportunities LP"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities LP. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities LP. Each of Opportunities GP and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held directly by Opportunities LP, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the issuer and files separate Section 16 reports.

Filing footnotes · ownership attribution and instrument terms

F1: The shares are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held directly by Ventures VI, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the issuer and files separate Section 16 reports.

F2: The shares are directly held by 5AM Opportunities I, L.P ("Opportunities LP"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities LP. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities LP. Each of Opportunities GP and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held directly by Opportunities LP, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the issuer and files separate Section 16 reports.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Section 16 reporting ended · disclosed 2026-08-05. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Pre-Funded Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00IndirectBy 5AM Ventures VII, L.P.3,179,558 Reported balance After 2026-08-03 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-08-03 · Purchase · Acquired 3,179,558 · Balance 3,179,558

F1: The Pre-Funded Warrant has no expiration date and is exercisable immediately. Notwithstanding the foregoing, 5AM Ventures VII, L.P. ("Ventures VII") shall not be entitled to exercise the Pre-Funded Warrant to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by Ventures VII, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.

F2: The shares are directly held by Ventures VII. 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.

Filing footnotes · ownership attribution and instrument terms

F1: The Pre-Funded Warrant has no expiration date and is exercisable immediately. Notwithstanding the foregoing, 5AM Ventures VII, L.P. ("Ventures VII") shall not be entitled to exercise the Pre-Funded Warrant to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by Ventures VII, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.

F2: The shares are directly held by Ventures VII. 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.

Section 16 reporting ended · disclosed 2023-02-28. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy 5AM Ventures VI, L.P.0 Reported balance After 2023-02-24 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2023-02-24 · Other · Disposed 3,953,990 · Balance 0

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the "Issuer"), AstraZeneca Finance and Holdings Inc. ("Parent") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent ("Purchaser"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (i) $26.00 per Share in cash (the "Cash Amount"), plus (ii) one contingent value right (each, a "CVR") per Share representing the right to receive a contingent payment of $10.00 per share, [continues to footnote (2)]

F2: [continues from footnote (1)] in cash, upon the achievement of a specified milestone by December 31, 2033 (the Cash Amount plus one CVR, collectively, the "Offer Price"), in each case, without interest, subject to any applicable withholding taxes. Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price.

F3: Shares are held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy 5AM Opportunities II, L.P.0 Reported balance After 2023-02-24 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2023-02-24 · Other · Disposed 487,333 · Balance 0

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the "Issuer"), AstraZeneca Finance and Holdings Inc. ("Parent") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent ("Purchaser"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (i) $26.00 per Share in cash (the "Cash Amount"), plus (ii) one contingent value right (each, a "CVR") per Share representing the right to receive a contingent payment of $10.00 per share, [continues to footnote (2)]

F2: [continues from footnote (1)] in cash, upon the achievement of a specified milestone by December 31, 2033 (the Cash Amount plus one CVR, collectively, the "Offer Price"), in each case, without interest, subject to any applicable withholding taxes. Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price.

F4: Shares are held by 5AM Opportunities II, L.P. ("Opportunities II"). 5AM Opportunities II (GP), LLC ("Opportunities II GP") is the sole general partner of Opportunities II. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities II GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities II. Each of Opportunities II GP, Mr. Schwab and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy 5AM Opportunities I, L.P.0 Reported balance After 2023-02-24 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 3 · 2023-02-24 · Other · Disposed 496,323 · Balance 0

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the "Issuer"), AstraZeneca Finance and Holdings Inc. ("Parent") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent ("Purchaser"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (i) $26.00 per Share in cash (the "Cash Amount"), plus (ii) one contingent value right (each, a "CVR") per Share representing the right to receive a contingent payment of $10.00 per share, [continues to footnote (2)]

F2: [continues from footnote (1)] in cash, upon the achievement of a specified milestone by December 31, 2033 (the Cash Amount plus one CVR, collectively, the "Offer Price"), in each case, without interest, subject to any applicable withholding taxes. Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price.

F5: Shares are held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP, Mr. Schwab and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the "Issuer"), AstraZeneca Finance and Holdings Inc. ("Parent") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent ("Purchaser"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (i) $26.00 per Share in cash (the "Cash Amount"), plus (ii) one contingent value right (each, a "CVR") per Share representing the right to receive a contingent payment of $10.00 per share, [continues to footnote (2)]

F2: [continues from footnote (1)] in cash, upon the achievement of a specified milestone by December 31, 2033 (the Cash Amount plus one CVR, collectively, the "Offer Price"), in each case, without interest, subject to any applicable withholding taxes. Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price.

F3: Shares are held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

F4: Shares are held by 5AM Opportunities II, L.P. ("Opportunities II"). 5AM Opportunities II (GP), LLC ("Opportunities II GP") is the sole general partner of Opportunities II. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities II GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities II. Each of Opportunities II GP, Mr. Schwab and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

F5: Shares are held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP, Mr. Schwab and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

Enliven Therapeutics, Inc.

Report date February 14, 2024 · Filed February 16, 2024

Jointly reported with 5AM Ventures VI, L.P., 5AM Opportunities I (GP), LLC, 5AM Opportunities I, L.P., PARMAR KUSH, Schwab Andrew J.

Section 16 reporting ended · disclosed 2024-02-16. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy 5AMVentures VI, L.P.3,200,634 Reported balance After 2024-02-14 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2024-02-14 · Sale · Disposed 688,358 · Balance 3,200,634

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.89 to $14.93 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: The shares are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy 5AM Opportunities I, L.P.635,341 Reported balance After 2024-02-14 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2024-02-14 · Sale · Disposed 136,642 · Balance 635,341

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.89 to $14.93 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The shares are directly held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP, Dr. Parmar and Mr. Schwab disclaims beneficial ownership of such shares, except to the extent of its or his respective pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.89 to $14.93 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: The shares are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein.

F3: The shares are directly held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP, Dr. Parmar and Mr. Schwab disclaims beneficial ownership of such shares, except to the extent of its or his respective pecuniary interest therein.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
August 10, 2026 Filed Aug 12, 2026 20:13 UTC Latigo Biotherapeutics, Inc. LTGO · Entity 4709 ConversionSeries B Preferred Stock · Derivative 1,484,401 $0.00 $0.00
Disclosure

SEC source: 0001231919-26-000869 · form4-08122026_080846.xml · derivative · entry 6

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Opportunities II, L.P. · CIK 0001844401 · 10% owner

5AM Opportunities II (GP), LLC · CIK 0001873515 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By 5AM Opportunities II, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 1,484,401 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date.

F3 · ownership.nature: The securities are directly held by 5AM Opportunities II, L.P. ("Opportunities II"). 5AM Opportunities II (GP), LLC ("Opportunities II GP") is the general partner of Opportunities II and may be deemed to have sole investment and voting power over the securities held by Opportunities II. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Opportunities II GP and may be deemed to have shared voting and investment power over the securities beneficially owned by Opportunities II. Each of Opportunities II GP, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein.

Read SEC document
August 10, 2026 Filed Aug 12, 2026 20:13 UTC Latigo Biotherapeutics, Inc. LTGO · Entity 4709 ConversionSeries A-2 Preferred Stock · Derivative 866,018 $0.00 $0.00
Disclosure

SEC source: 0001231919-26-000869 · form4-08122026_080846.xml · derivative · entry 5

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Opportunities II, L.P. · CIK 0001844401 · 10% owner

5AM Opportunities II (GP), LLC · CIK 0001873515 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By 5AM Opportunities II, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 866,018 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date.

F3 · ownership.nature: The securities are directly held by 5AM Opportunities II, L.P. ("Opportunities II"). 5AM Opportunities II (GP), LLC ("Opportunities II GP") is the general partner of Opportunities II and may be deemed to have sole investment and voting power over the securities held by Opportunities II. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Opportunities II GP and may be deemed to have shared voting and investment power over the securities beneficially owned by Opportunities II. Each of Opportunities II GP, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein.

Read SEC document
August 10, 2026 Filed Aug 12, 2026 20:13 UTC Latigo Biotherapeutics, Inc. LTGO · Entity 4709 ConversionSeries A-2 Preferred Stock · Derivative 1,823,238 $0.00 $0.00
Disclosure

SEC source: 0001231919-26-000869 · form4-08122026_080846.xml · derivative · entry 4

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Opportunities II, L.P. · CIK 0001844401 · 10% owner

5AM Opportunities II (GP), LLC · CIK 0001873515 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By 5AM Ventures VI, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 1,823,238 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date.

F2 · ownership.nature: The securities are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein.

Read SEC document
August 10, 2026 Filed Aug 12, 2026 20:13 UTC Latigo Biotherapeutics, Inc. LTGO · Entity 4709 ConversionSeries A Preferred Stock · Derivative 3,152,305 $0.00 $0.00
Disclosure

SEC source: 0001231919-26-000869 · form4-08122026_080846.xml · derivative · entry 3

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Opportunities II, L.P. · CIK 0001844401 · 10% owner

5AM Opportunities II (GP), LLC · CIK 0001873515 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By 5AM Ventures VI, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 3,152,305 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date.

F2 · ownership.nature: The securities are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein.

Read SEC document
August 10, 2026 Filed Aug 12, 2026 20:13 UTC Latigo Biotherapeutics, Inc. LTGO · Entity 4709 ConversionCommon Stock 2,350,419 Not disclosed Not disclosed
Disclosure

SEC source: 0001231919-26-000869 · form4-08122026_080846.xml · nonDerivative · entry 2

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Opportunities II, L.P. · CIK 0001844401 · 10% owner

5AM Opportunities II (GP), LLC · CIK 0001873515 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By 5AM Opportunities II, L.P.

Disclosed balance after: 2,350,419

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date.

F3 · ownership.nature: The securities are directly held by 5AM Opportunities II, L.P. ("Opportunities II"). 5AM Opportunities II (GP), LLC ("Opportunities II GP") is the general partner of Opportunities II and may be deemed to have sole investment and voting power over the securities held by Opportunities II. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Opportunities II GP and may be deemed to have shared voting and investment power over the securities beneficially owned by Opportunities II. Each of Opportunities II GP, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein.

Read SEC document
August 10, 2026 Filed Aug 12, 2026 20:13 UTC Latigo Biotherapeutics, Inc. LTGO · Entity 4709 ConversionCommon Stock 4,975,543 Not disclosed Not disclosed
Disclosure

SEC source: 0001231919-26-000869 · form4-08122026_080846.xml · nonDerivative · entry 1

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Opportunities II, L.P. · CIK 0001844401 · 10% owner

5AM Opportunities II (GP), LLC · CIK 0001873515 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By 5AM Ventures VI, L.P.

Disclosed balance after: 4,975,543

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date.

F2 · ownership.nature: The securities are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein.

Read SEC document
August 03, 2026 Filed Aug 5, 2026 21:39 UTC Camp4 Therapeutics Corp CAMP · Entity 1161 PurchasePre-Funded Warrant (Right to Buy) · Derivative 3,179,558 $1.53 Strike: $0.00 $4,864,405.78
Disclosure

SEC source: 0001231919-26-000829 · form4-08052026_090822.xml · derivative · entry 1

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Opportunities II (GP), LLC · CIK 0001873515 · 10% owner

5AM Opportunities II, L.P. · CIK 0001844401 · 10% owner

5AM Partners VII, LLC · CIK 0001873545 · 10% owner

5AM Ventures VII, L.P. · CIK 0001844435 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By 5AM Ventures VII, L.P.

Disclosed balance after: 3,179,558

Underlying: Common Stock · 3,179,558 shares

Expires not disclosed

F1 · derivative.exercise_date: The Pre-Funded Warrant has no expiration date and is exercisable immediately. Notwithstanding the foregoing, 5AM Ventures VII, L.P. ("Ventures VII") shall not be entitled to exercise the Pre-Funded Warrant to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by Ventures VII, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.

F1 · derivative.expiration_date: The Pre-Funded Warrant has no expiration date and is exercisable immediately. Notwithstanding the foregoing, 5AM Ventures VII, L.P. ("Ventures VII") shall not be entitled to exercise the Pre-Funded Warrant to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by Ventures VII, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.

F2 · ownership.nature: The shares are directly held by Ventures VII. 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.

Read SEC document
September 11, 2025 Filed Sep 16, 2025 00:12 UTC Camp4 Therapeutics Corp CAMP · Entity 1161 PurchaseCommon Stock 2,941,176 $1.53 $4,499,999.28
Disclosure

SEC source: 0001231919-25-000196 · form4-09152025_100930.xml · nonDerivative · entry 1

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Opportunities II (GP), LLC · CIK 0001873515 · 10% owner

5AM Opportunities II, L.P. · CIK 0001844401 · 10% owner

5AM Partners VII, LLC · CIK 0001873545 · 10% owner

5AM Ventures VII, L.P. · CIK 0001844435 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By 5AM Ventures VII, L.P.

Disclosed balance after: 2,941,176

F1 · ownership.nature: The shares are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.

Read SEC document
October 15, 2024 Filed Oct 15, 2024 21:56 UTC Camp4 Therapeutics Corp CAMP · Entity 1161 ConversionSeries B Preferred Stock · Derivative 3,395,816 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-24-025140 · form4-10152024_091031.xml · derivative · entry 6

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Opportunities II (GP), LLC · CIK 0001873515 · 10% owner

5AM Opportunities II, L.P. · CIK 0001844401 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By 5AM Opportunities II, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 302,770 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F1 · price: Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F3 · ownership.nature: The shares are directly held by 5AM Opportunities II, L.P. ("Opportunities II"). 5AM Opportunities II (GP), LLC ("Opportunities II GP") is the sole general partner of Opportunities II. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities II GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities II. Each of Opportunities II GP and Dr. Parmar disclaims beneficial ownership of such shares, except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.

Read SEC document
October 15, 2024 Filed Oct 15, 2024 21:56 UTC Camp4 Therapeutics Corp CAMP · Entity 1161 ConversionSeries B Preferred Stock · Derivative 4,244,770 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-24-025140 · form4-10152024_091031.xml · derivative · entry 5

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Opportunities II (GP), LLC · CIK 0001873515 · 10% owner

5AM Opportunities II, L.P. · CIK 0001844401 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By 5AM Ventures VI, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 378,463 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F1 · price: Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F2 · ownership.nature: The shares are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.

Read SEC document
October 15, 2024 Filed Oct 15, 2024 21:56 UTC Camp4 Therapeutics Corp CAMP · Entity 1161 ConversionSeries A Prime Preferred Stock · Derivative 15,002,166 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-24-025140 · form4-10152024_091031.xml · derivative · entry 4

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Opportunities II (GP), LLC · CIK 0001873515 · 10% owner

5AM Opportunities II, L.P. · CIK 0001844401 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By 5AM Ventures VI, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 1,337,592 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F1 · price: Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F2 · ownership.nature: The shares are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.

Read SEC document
October 15, 2024 Filed Oct 15, 2024 21:56 UTC Camp4 Therapeutics Corp CAMP · Entity 1161 PurchaseCommon Stock 909,090 $11.00 $9,999,990.00
Disclosure

SEC source: 0001415889-24-025140 · form4-10152024_091031.xml · nonDerivative · entry 3

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Opportunities II (GP), LLC · CIK 0001873515 · 10% owner

5AM Opportunities II, L.P. · CIK 0001844401 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By 5AM Ventures VI, L.P.

Disclosed balance after: 2,625,145

F2 · ownership.nature: The shares are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.

Read SEC document
October 15, 2024 Filed Oct 15, 2024 21:56 UTC Camp4 Therapeutics Corp CAMP · Entity 1161 ConversionCommon Stock 302,770 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-24-025140 · form4-10152024_091031.xml · nonDerivative · entry 2

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Opportunities II (GP), LLC · CIK 0001873515 · 10% owner

5AM Opportunities II, L.P. · CIK 0001844401 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By 5AM Opportunities II, L.P.

Disclosed balance after: 302,770

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F3 · ownership.nature: The shares are directly held by 5AM Opportunities II, L.P. ("Opportunities II"). 5AM Opportunities II (GP), LLC ("Opportunities II GP") is the sole general partner of Opportunities II. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities II GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities II. Each of Opportunities II GP and Dr. Parmar disclaims beneficial ownership of such shares, except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.

Read SEC document
October 15, 2024 Filed Oct 15, 2024 21:56 UTC Camp4 Therapeutics Corp CAMP · Entity 1161 ConversionCommon Stock 1,716,055 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-24-025140 · form4-10152024_091031.xml · nonDerivative · entry 1

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Opportunities II (GP), LLC · CIK 0001873515 · 10% owner

5AM Opportunities II, L.P. · CIK 0001844401 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By 5AM Ventures VI, L.P.

Disclosed balance after: 1,716,055

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F2 · ownership.nature: The shares are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.

Read SEC document
July 22, 2024 Filed Jul 24, 2024 20:15 UTC Artiva Biotherapeutics, Inc. ARTV · Entity 5404 ConversionSeries B Preferred Stock · Derivative 214,692 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-24-020035 · form4-07242024_040705.xml · derivative · entry 6

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Opportunities II (GP), LLC · CIK 0001873515 · 10% owner

5AM Opportunities II, L.P. · CIK 0001844401 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By 5AM Ventures VI, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 214,692 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F2 · ownership.nature: The shares are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein.

Read SEC document
July 22, 2024 Filed Jul 24, 2024 20:15 UTC Artiva Biotherapeutics, Inc. ARTV · Entity 5404 ConversionSeries A Preferred Stock · Derivative 843,592 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-24-020035 · form4-07242024_040705.xml · derivative · entry 5

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Opportunities II (GP), LLC · CIK 0001873515 · 10% owner

5AM Opportunities II, L.P. · CIK 0001844401 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By 5AM Ventures VI, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 843,592 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F2 · ownership.nature: The shares are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein.

Read SEC document
July 22, 2024 Filed Jul 24, 2024 20:15 UTC Artiva Biotherapeutics, Inc. ARTV · Entity 5404 PurchaseCommon Stock 833,333 $12.00 $9,999,996.00
Disclosure

SEC source: 0001415889-24-020035 · form4-07242024_040705.xml · nonDerivative · entry 4

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Opportunities II (GP), LLC · CIK 0001873515 · 10% owner

5AM Opportunities II, L.P. · CIK 0001844401 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By 5AM Opportunities II, L.P.

Disclosed balance after: 1,182,054

F5 · ownership.nature: Shares are held by 5AM Opportunities II, L.P. ("Opportunities II"). 5AM Opportunities II (GP), LLC ("Opportunities II GP") is the general partner of Opportunities II and may be deemed to have sole investment and voting power over the shares held by Opportunities II. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Opportunities II GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities II. Each of Opportunities II GP, Dr. Parmar and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein.

Read SEC document
July 22, 2024 Filed Jul 24, 2024 20:15 UTC Artiva Biotherapeutics, Inc. ARTV · Entity 5404 OtherCommon Stock 348,721 $10.20 $3,556,954.20
Disclosure

SEC source: 0001415889-24-020035 · form4-07242024_040705.xml · nonDerivative · entry 3

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Opportunities II (GP), LLC · CIK 0001873515 · 10% owner

5AM Opportunities II, L.P. · CIK 0001844401 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By 5AM Opportunities II, L.P.

Disclosed balance after: 348,721

F4 · kind: Represents the conversion of outstanding simple agreement for future equity in the amount of $3,556,957.78 into shares of the Issuer's common stock upon closing of the Issuer's IPO at a 15% discount to the IPO price.

F5 · ownership.nature: Shares are held by 5AM Opportunities II, L.P. ("Opportunities II"). 5AM Opportunities II (GP), LLC ("Opportunities II GP") is the general partner of Opportunities II and may be deemed to have sole investment and voting power over the shares held by Opportunities II. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Opportunities II GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities II. Each of Opportunities II GP, Dr. Parmar and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein.

Read SEC document
July 22, 2024 Filed Jul 24, 2024 20:15 UTC Artiva Biotherapeutics, Inc. ARTV · Entity 5404 OtherCommon Stock 112,966 $10.20 $1,152,253.20
Disclosure

SEC source: 0001415889-24-020035 · form4-07242024_040705.xml · nonDerivative · entry 2

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Opportunities II (GP), LLC · CIK 0001873515 · 10% owner

5AM Opportunities II, L.P. · CIK 0001844401 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By 5AM Ventures VI, L.P.

Disclosed balance after: 1,171,250

F3 · kind: Represents the conversion of outstanding simple agreement for future equity in the amount of $1,152,253.93 into shares of the Issuer's common stock upon closing of the Issuer's IPO at a 15% discount to the IPO price.

F2 · ownership.nature: The shares are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein.

Read SEC document
July 22, 2024 Filed Jul 24, 2024 20:15 UTC Artiva Biotherapeutics, Inc. ARTV · Entity 5404 ConversionCommon Stock 1,058,284 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-24-020035 · form4-07242024_040705.xml · nonDerivative · entry 1

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Opportunities II (GP), LLC · CIK 0001873515 · 10% owner

5AM Opportunities II, L.P. · CIK 0001844401 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By 5AM Ventures VI, L.P.

Disclosed balance after: 1,058,284

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F2 · ownership.nature: The shares are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein.

Read SEC document
February 14, 2024 Filed Feb 16, 2024 21:15 UTC Enliven Therapeutics, Inc. ELVN · Entity 4024 SaleCommon Stock 136,642 $14.90 $2,035,965.80
Disclosure

SEC source: 0001415889-24-004111 · form4-02162024_040204.xml · nonDerivative · entry 2

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By 5AM Opportunities I, L.P.

Disclosed balance after: 635,341

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.89 to $14.93 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The shares are directly held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP, Dr. Parmar and Mr. Schwab disclaims beneficial ownership of such shares, except to the extent of its or his respective pecuniary interest therein.

Read SEC document
February 14, 2024 Filed Feb 16, 2024 21:15 UTC Enliven Therapeutics, Inc. ELVN · Entity 4024 SaleCommon Stock 688,358 $14.90 $10,256,534.20
Disclosure

SEC source: 0001415889-24-004111 · form4-02162024_040204.xml · nonDerivative · entry 1

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By 5AMVentures VI, L.P.

Disclosed balance after: 3,200,634

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.89 to $14.93 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · ownership.nature: The shares are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein.

Read SEC document
January 31, 2024 Filed Feb 2, 2024 21:29 UTC Enliven Therapeutics, Inc. ELVN · Entity 4024 SaleCommon Stock 82,813 $15.00 $1,242,195.00
Disclosure

SEC source: 0001415889-24-002295 · form4-02022024_090230.xml · nonDerivative · entry 2

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By 5AM Opportunities I, L.P.

Disclosed balance after: 771,983

F2 · ownership.nature: The shares are directly held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP, Dr. Parmar and Mr. Schwab disclaims beneficial ownership of such shares, except to the extent of its or his respective pecuniary interest therein.

Read SEC document
January 31, 2024 Filed Feb 2, 2024 21:29 UTC Enliven Therapeutics, Inc. ELVN · Entity 4024 SaleCommon Stock 417,187 $15.00 $6,257,805.00
Disclosure

SEC source: 0001415889-24-002295 · form4-02022024_090230.xml · nonDerivative · entry 1

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By 5AMVentures VI, L.P.

Disclosed balance after: 3,888,992

F1 · ownership.nature: The shares are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein.

Read SEC document
September 26, 2023 Filed Sep 28, 2023 20:27 UTC Enliven Therapeutics, Inc. ELVN · Entity 4024 SaleCommon Stock 32,711 $15.00 $490,665.00
Disclosure

SEC source: 0001209191-23-050731 · doc4.xml · nonDerivative · entry 2

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By 5AM Opportunities I, L.P.

Disclosed balance after: 854,796

F2 · ownership.nature: The shares are directly held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP, Dr. Parmar and Mr. Schwab disclaims beneficial ownership of such shares, except to the extent of its or his respective pecuniary interest therein.

Read SEC document
September 26, 2023 Filed Sep 28, 2023 20:27 UTC Enliven Therapeutics, Inc. ELVN · Entity 4024 SaleCommon Stock 164,789 $15.00 $2,471,835.00
Disclosure

SEC source: 0001209191-23-050731 · doc4.xml · nonDerivative · entry 1

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By 5AM Ventures VI, L.P.

Disclosed balance after: 4,306,179

F1 · ownership.nature: The shares are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein.

Read SEC document
August 24, 2023 Filed Aug 28, 2023 20:20 UTC Enliven Therapeutics, Inc. ELVN · Entity 4024 SaleCommon Stock 72,876 $16.00 $1,166,016.00
Disclosure

SEC source: 0001209191-23-047514 · doc4.xml · nonDerivative · entry 2

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By 5AM Opportunities I, L.P.

Disclosed balance after: 887,507

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.60 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The shares are directly held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP, Dr. Parmar and Mr. Schwab disclaims beneficial ownership of such shares, except to the extent of its or his respective pecuniary interest therein.

Read SEC document
August 24, 2023 Filed Aug 28, 2023 20:20 UTC Enliven Therapeutics, Inc. ELVN · Entity 4024 SaleCommon Stock 367,124 $16.00 $5,873,984.00
Disclosure

SEC source: 0001209191-23-047514 · doc4.xml · nonDerivative · entry 1

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By 5AM Ventures VI, L.P.

Disclosed balance after: 4,470,968

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.60 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · ownership.nature: The shares are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein.

Read SEC document
February 24, 2023 Filed Feb 28, 2023 21:29 UTC CinCor Pharma, Inc. CINC · Entity 116342 OtherCommon Stock 496,323 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-013671 · doc4.xml · nonDerivative · entry 3

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

5AM Opportunities II (GP), LLC · CIK 0001873515 · 10% owner

5AM Opportunities II, L.P. · CIK 0001844401 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By 5AM Opportunities I, L.P.

Disclosed balance after: 0

F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the "Issuer"), AstraZeneca Finance and Holdings Inc. ("Parent") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent ("Purchaser"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (i) $26.00 per Share in cash (the "Cash Amount"), plus (ii) one contingent value right (each, a "CVR") per Share representing the right to receive a contingent payment of $10.00 per share, [continues to footnote (2)]

F2 · shares: [continues from footnote (1)] in cash, upon the achievement of a specified milestone by December 31, 2033 (the Cash Amount plus one CVR, collectively, the "Offer Price"), in each case, without interest, subject to any applicable withholding taxes. Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price.

F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the "Issuer"), AstraZeneca Finance and Holdings Inc. ("Parent") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent ("Purchaser"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (i) $26.00 per Share in cash (the "Cash Amount"), plus (ii) one contingent value right (each, a "CVR") per Share representing the right to receive a contingent payment of $10.00 per share, [continues to footnote (2)]

F2 · price: [continues from footnote (1)] in cash, upon the achievement of a specified milestone by December 31, 2033 (the Cash Amount plus one CVR, collectively, the "Offer Price"), in each case, without interest, subject to any applicable withholding taxes. Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price.

F5 · ownership.nature: Shares are held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP, Mr. Schwab and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

Read SEC document
February 24, 2023 Filed Feb 28, 2023 21:29 UTC CinCor Pharma, Inc. CINC · Entity 116342 OtherCommon Stock 487,333 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-013671 · doc4.xml · nonDerivative · entry 2

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

5AM Opportunities II (GP), LLC · CIK 0001873515 · 10% owner

5AM Opportunities II, L.P. · CIK 0001844401 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By 5AM Opportunities II, L.P.

Disclosed balance after: 0

F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the "Issuer"), AstraZeneca Finance and Holdings Inc. ("Parent") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent ("Purchaser"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (i) $26.00 per Share in cash (the "Cash Amount"), plus (ii) one contingent value right (each, a "CVR") per Share representing the right to receive a contingent payment of $10.00 per share, [continues to footnote (2)]

F2 · shares: [continues from footnote (1)] in cash, upon the achievement of a specified milestone by December 31, 2033 (the Cash Amount plus one CVR, collectively, the "Offer Price"), in each case, without interest, subject to any applicable withholding taxes. Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price.

F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the "Issuer"), AstraZeneca Finance and Holdings Inc. ("Parent") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent ("Purchaser"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (i) $26.00 per Share in cash (the "Cash Amount"), plus (ii) one contingent value right (each, a "CVR") per Share representing the right to receive a contingent payment of $10.00 per share, [continues to footnote (2)]

F2 · price: [continues from footnote (1)] in cash, upon the achievement of a specified milestone by December 31, 2033 (the Cash Amount plus one CVR, collectively, the "Offer Price"), in each case, without interest, subject to any applicable withholding taxes. Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price.

F4 · ownership.nature: Shares are held by 5AM Opportunities II, L.P. ("Opportunities II"). 5AM Opportunities II (GP), LLC ("Opportunities II GP") is the sole general partner of Opportunities II. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities II GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities II. Each of Opportunities II GP, Mr. Schwab and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

Read SEC document
February 24, 2023 Filed Feb 28, 2023 21:29 UTC CinCor Pharma, Inc. CINC · Entity 116342 OtherCommon Stock 3,953,990 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-013671 · doc4.xml · nonDerivative · entry 1

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

5AM Opportunities II (GP), LLC · CIK 0001873515 · 10% owner

5AM Opportunities II, L.P. · CIK 0001844401 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By 5AM Ventures VI, L.P.

Disclosed balance after: 0

F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the "Issuer"), AstraZeneca Finance and Holdings Inc. ("Parent") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent ("Purchaser"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (i) $26.00 per Share in cash (the "Cash Amount"), plus (ii) one contingent value right (each, a "CVR") per Share representing the right to receive a contingent payment of $10.00 per share, [continues to footnote (2)]

F2 · shares: [continues from footnote (1)] in cash, upon the achievement of a specified milestone by December 31, 2033 (the Cash Amount plus one CVR, collectively, the "Offer Price"), in each case, without interest, subject to any applicable withholding taxes. Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price.

F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the "Issuer"), AstraZeneca Finance and Holdings Inc. ("Parent") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent ("Purchaser"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (i) $26.00 per Share in cash (the "Cash Amount"), plus (ii) one contingent value right (each, a "CVR") per Share representing the right to receive a contingent payment of $10.00 per share, [continues to footnote (2)]

F2 · price: [continues from footnote (1)] in cash, upon the achievement of a specified milestone by December 31, 2033 (the Cash Amount plus one CVR, collectively, the "Offer Price"), in each case, without interest, subject to any applicable withholding taxes. Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price.

F3 · ownership.nature: Shares are held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

Read SEC document
August 15, 2022 Filed Aug 18, 2022 00:01 UTC CinCor Pharma, Inc. CINC · Entity 116342 PurchaseCommon Stock 487,333 $30.00 $14,619,990.00
Disclosure

SEC source: 0001209191-22-046494 · doc4.xml · nonDerivative · entry 2

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

5AM Opportunities II (GP), LLC · CIK 0001873515 · 10% owner

5AM Opportunities II, L.P. · CIK 0001844401 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By 5AM Opportunities II, L.P.

Disclosed balance after: 487,333

F2 · ownership.nature: Shares are held by 5AM Opportunities II, L.P. ("Opportunities II"). 5AM Opportunities II (GP), LLC ("Opportunities II GP") is the sole general partner of Opportunities II. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities II GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities II. Each of Opportunities II GP, Mr. Schwab and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

Read SEC document
August 15, 2022 Filed Aug 18, 2022 00:01 UTC CinCor Pharma, Inc. CINC · Entity 116342 PurchaseCommon Stock 112,667 $30.00 $3,380,010.00
Disclosure

SEC source: 0001209191-22-046494 · doc4.xml · nonDerivative · entry 1

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

5AM Opportunities II (GP), LLC · CIK 0001873515 · 10% owner

5AM Opportunities II, L.P. · CIK 0001844401 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By 5AM Ventures VI, L.P.

Disclosed balance after: 3,953,990

F1 · ownership.nature: The shares are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

Read SEC document
January 11, 2022 Filed Jan 13, 2022 21:45 UTC CinCor Pharma, Inc. CINC · Entity 116342 ConversionSeries B Preferred Stock · Derivative 625,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-003205 · doc4.xml · derivative · entry 7

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By 5AM Opportunities I, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 183,823 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a 3.4:1 basis, and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a 3.4:1 basis, and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a 3.4:1 basis, and had no expiration date.

F3 · ownership.nature: Shares are held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP, Mr. Schwab and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

Read SEC document
January 11, 2022 Filed Jan 13, 2022 21:45 UTC CinCor Pharma, Inc. CINC · Entity 116342 ConversionSeries B Preferred Stock · Derivative 2,525,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-003205 · doc4.xml · derivative · entry 6

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By 5AM Ventures VI, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 742,647 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a 3.4:1 basis, and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a 3.4:1 basis, and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a 3.4:1 basis, and had no expiration date.

F2 · ownership.nature: The shares are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

Read SEC document
January 11, 2022 Filed Jan 13, 2022 21:45 UTC CinCor Pharma, Inc. CINC · Entity 116342 ConversionSeries A Preferred Stock · Derivative 9,999,999 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-003205 · doc4.xml · derivative · entry 5

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By 5AM Ventures VI, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 2,941,176 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a 3.4:1 basis, and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a 3.4:1 basis, and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a 3.4:1 basis, and had no expiration date.

F2 · ownership.nature: The shares are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

Read SEC document
January 11, 2022 Filed Jan 13, 2022 21:45 UTC CinCor Pharma, Inc. CINC · Entity 116342 PurchaseCommon Stock 312,500 $16.00 $5,000,000.00
Disclosure

SEC source: 0001209191-22-003205 · doc4.xml · nonDerivative · entry 4

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By 5AM Opportunities I, L.P.

Disclosed balance after: 496,323

F3 · ownership.nature: Shares are held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP, Mr. Schwab and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

Read SEC document
January 11, 2022 Filed Jan 13, 2022 21:45 UTC CinCor Pharma, Inc. CINC · Entity 116342 PurchaseCommon Stock 157,500 $16.00 $2,520,000.00
Disclosure

SEC source: 0001209191-22-003205 · doc4.xml · nonDerivative · entry 3

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By 5AM Ventures VI, L.P.

Disclosed balance after: 3,841,323

F2 · ownership.nature: The shares are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

Read SEC document
January 11, 2022 Filed Jan 13, 2022 21:45 UTC CinCor Pharma, Inc. CINC · Entity 116342 ConversionCommon Stock 183,823 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-003205 · doc4.xml · nonDerivative · entry 2

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By 5AM Opportunities I, L.P.

Disclosed balance after: 183,823

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a 3.4:1 basis, and had no expiration date.

F3 · ownership.nature: Shares are held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP, Mr. Schwab and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

Read SEC document
January 11, 2022 Filed Jan 13, 2022 21:45 UTC CinCor Pharma, Inc. CINC · Entity 116342 ConversionCommon Stock 3,683,823 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-003205 · doc4.xml · nonDerivative · entry 1

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By 5AM Ventures VI, L.P.

Disclosed balance after: 3,683,823

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a 3.4:1 basis, and had no expiration date.

F2 · ownership.nature: The shares are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

Read SEC document
November 16, 2021 Filed Nov 19, 2021 01:14 UTC Vor Biopharma Inc. VOR · Entity 4763 SaleCommon Stock 91,836 $15.30 $1,405,090.80
Disclosure

SEC source: 0001209191-21-065661 · doc4.xml · nonDerivative · entry 2

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,766,634

F2 · ownership.nature: The shares are directly held by 5AM Opportunities I, L.P ("Opportunities LP"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities LP. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities LP. Each of Opportunities GP and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held directly by Opportunities LP, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the issuer and files separate Section 16 reports.

Read SEC document
November 16, 2021 Filed Nov 19, 2021 01:14 UTC Vor Biopharma Inc. VOR · Entity 4763 SaleCommon Stock 238,870 $15.30 $3,654,711.00
Disclosure

SEC source: 0001209191-21-065661 · doc4.xml · nonDerivative · entry 1

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,595,089

F1 · ownership.nature: The shares are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held directly by Ventures VI, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the issuer and files separate Section 16 reports.

Read SEC document
February 09, 2021 Filed Feb 9, 2021 23:03 UTC Vor Biopharma Inc. VOR · Entity 4763 ConversionSeries B Preferred Stock · Derivative 19,230,768 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-008925 · doc4.xml · derivative · entry 8

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,414,026 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 13.6 for-one basis, and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 13.6 for-one basis, and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 13.6 for-one basis, and had no expiration date.

F3 · ownership.nature: The shares are directly held by 5AM Opportunities I, L.P ("Opportunities LP"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities LP. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities LP. Each of Opportunities GP and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held directly by Opportunities LP, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the issuer and files separate Section 16 reports.

Read SEC document
February 09, 2021 Filed Feb 9, 2021 23:03 UTC Vor Biopharma Inc. VOR · Entity 4763 ConversionSeries B Preferred Stock · Derivative 19,230,768 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-008925 · doc4.xml · derivative · entry 7

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,414,026 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 13.6 for-one basis, and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 13.6 for-one basis, and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 13.6 for-one basis, and had no expiration date.

F2 · ownership.nature: The shares are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held directly by Ventures VI, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the issuer and files separate Section 16 reports.

Read SEC document
February 09, 2021 Filed Feb 9, 2021 23:03 UTC Vor Biopharma Inc. VOR · Entity 4763 ConversionSeries A-2 Preferred Stock · Derivative 45,000,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-008925 · doc4.xml · derivative · entry 6

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 3,308,822 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 13.6 for-one basis, and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 13.6 for-one basis, and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 13.6 for-one basis, and had no expiration date.

F2 · ownership.nature: The shares are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held directly by Ventures VI, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the issuer and files separate Section 16 reports.

Read SEC document
February 09, 2021 Filed Feb 9, 2021 23:03 UTC Vor Biopharma Inc. VOR · Entity 4763 PurchaseCommon Stock 444,444 $18.00 $7,999,992.00
Disclosure

SEC source: 0001209191-21-008925 · doc4.xml · nonDerivative · entry 5

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,858,470

F3 · ownership.nature: The shares are directly held by 5AM Opportunities I, L.P ("Opportunities LP"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities LP. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities LP. Each of Opportunities GP and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held directly by Opportunities LP, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the issuer and files separate Section 16 reports.

Read SEC document
February 09, 2021 Filed Feb 9, 2021 23:03 UTC Vor Biopharma Inc. VOR · Entity 4763 ConversionCommon Stock 1,414,026 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-008925 · doc4.xml · nonDerivative · entry 4

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,414,026

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 13.6 for-one basis, and had no expiration date.

F3 · ownership.nature: The shares are directly held by 5AM Opportunities I, L.P ("Opportunities LP"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities LP. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities LP. Each of Opportunities GP and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held directly by Opportunities LP, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the issuer and files separate Section 16 reports.

Read SEC document
February 09, 2021 Filed Feb 9, 2021 23:03 UTC Vor Biopharma Inc. VOR · Entity 4763 PurchaseCommon Stock 111,111 $18.00 $1,999,998.00
Disclosure

SEC source: 0001209191-21-008925 · doc4.xml · nonDerivative · entry 3

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,833,959

F2 · ownership.nature: The shares are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held directly by Ventures VI, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the issuer and files separate Section 16 reports.

Read SEC document
February 09, 2021 Filed Feb 9, 2021 23:03 UTC Vor Biopharma Inc. VOR · Entity 4763 ConversionCommon Stock 1,414,026 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-008925 · doc4.xml · nonDerivative · entry 2

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,722,848

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 13.6 for-one basis, and had no expiration date.

F2 · ownership.nature: The shares are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held directly by Ventures VI, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the issuer and files separate Section 16 reports.

Read SEC document
February 09, 2021 Filed Feb 9, 2021 23:03 UTC Vor Biopharma Inc. VOR · Entity 4763 ConversionCommon Stock 3,308,822 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-008925 · doc4.xml · nonDerivative · entry 1

5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner

5AM Partners VI, LLC · CIK 0001829051 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 3,308,822

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 13.6 for-one basis, and had no expiration date.

F2 · ownership.nature: The shares are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held directly by Ventures VI, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the issuer and files separate Section 16 reports.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.